Lung Cancer Dispatch
Follow
Find tag "nintedanib"
4.2K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Nintedanib: New Oral Angiogenesis Inhibitor in Lung Cancer

"A new oral angiogenesis inhibitor for the treatment of lung cancer could be edging closer to the market: Approval application for nintedanib (Boehringer Ingelheim) has been filed in Europe and is being prepared for the United States.


"The data for nintedanib come from the phase 3 trial known as LUME-Lung-1, recently published in the Lancet Oncology."


Editor's note: We previously posted a story about the potential benefits of the drug nintedanib for some patients with non-small cell lung cancer (NSCLC).

Cancer Commons's insight:

Medscape  |  Mar 28, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Cancer Drug Vargatef Extends Progression-Free Period in Lung Cancer

Patients treated with the new cancer drug nintedanib (Vargatef), in addition to second-line chemotherapy, experienced a longer delay before their lung cancer worsened, a recent phase III clinical trial showed. The study focused on patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed after a first round of chemotherapy. Trial participants received the chemotherapy agent docetaxel (Taxotere) either with or without Vargatef. Those treated with Vargatef went an average of 3.4 months before their cancer started to grow again, compared to 2.7 in patients who were given Taxotere alone. There was also evidence that Vargatef may increase overall survival, especially in patients with lung adenocarcinoma, a subtype of NSCLC.

Cancer Commons's insight:

PR Newswire | June 3, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Positive Results For Vargatef in Lung Cancer Study

Positive Results For Vargatef in Lung Cancer Study | Lung Cancer Dispatch | Scoop.it

New clinical trial results suggest that adding the drug nintedanib (Vargatef) to second-line chemotherapy can improve survival for some patients with non-small cell lung cancer (NSCLC). Patients with advanced NSCLC whose cancer had progressed after first-line chemotherapy received either Vargatef and the chemotherapy drug docetaxel (Taxotere) or Taxotere alone. On the whole, Vargatef was associated with slightly longer times without worsening of the cancer (3.4 months vs 2.7 in the Taxotere-only group), but no improvement in overall survival. However, in patients with lung adenocarcinoma, a subtype of NSCLC, the addition of Vargatef improved overall survival by over 2 months (12.6 months vs 10.3 with Taxotere alone). Vargatef disrupts the formation of new blood vessels that feed growing tumors.

Cancer Commons's insight:

Clinical Oncology News  |  Oct, 2013

more...
No comment yet.